The NextGen Group said this week its US subsidiary NextGen Sciences has signed a deal with the University of Nebraska for use of its csfdiscovery43 biomarker discovery assay.

Under the agreement, scientists at the Chronic HIV Infection and Aging in NeuroAIDS Center at the University of Nebraska Medical Center will use the assay to investigate biomarkers associated with cognitive abnormalities in patients chronically infected with HIV. The work will use the center's collection of well-characterized, longitudinal CSF samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.